Methylone demonstrates improvement in PTSD symptoms in Phase 2 study
The Brown University Psychopharmacology Update April 30, 2026 DOI: 10.1002/pu.31448 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase 2 randomized controlled trial Peer reviewed |
|---|---|
| Duration | Four weekly doses |
| Topics | PTSD |
| Keywords | Placebo Adverse effect Phase matter Posttraumatic stress Clinical psychology |
| Key findings | TSND-201 significantly reduced PTSD symptoms compared with placebo over four weekly doses. |
Abstract
Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study results were published online Feb. 18, 2026, in JAMA Psychiatry .